Bayer Files False Advertising Lawsuit Against Johnson & Johnson Over Cancer Drug
New York, Sunday, 1 March 2026.
Bayer alleges Johnson & Johnson utilized false advertising to undermine its rival prostate cancer drug, Nubeqa, a legal battle emerging even as JNJ shares trade significantly above analyst price targets.
Legal Confrontation in Manhattan Federal Court
In a significant escalation of pharmaceutical industry tensions, Bayer has filed a lawsuit against Johnson & Johnson in the U.S. District Court for the Southern District of New York [2]. The complaint, lodged on February 25, 2026, alleges that Johnson & Johnson engaged in a “false advertising campaign” designed to undermine Bayer’s prostate cancer treatment, Nubeqa, in favor of its own competing drug, Erleada [2]. This legal action arrives shortly after Bayer launched a high-profile marketing initiative featuring former NFL quarterback Tony Romo and his father, highlighting the intensifying competition for market share in the advanced prostate cancer sector [2]. According to the filing, Johnson & Johnson disseminated misleading claims regarding Nubeqa’s efficacy through a press release and presentations hosted on its Medical Connect website [2].
Johnson & Johnson Defends Data Integrity
Johnson & Johnson has firmly rejected the allegations, maintaining that its comparative analysis was grounded in sound scientific methodology [2]. In a statement addressing the lawsuit, the company asserted that “Litigation does not change data,” and argued that Bayer’s legal challenge reflects a misunderstanding of real-world evidence principles and methodological frameworks [2]. The dispute underscores the high stakes involved for Bayer; Stefan Oelrich, president of Bayer’s pharmaceuticals division, recently described Nubeqa as being “poised to become the number one product in prostate cancer” and potentially the largest product in the company’s history [2]. This push for pharmaceutical dominance coincides with Bayer’s broader efforts to resolve legacy liabilities, including a recent offer of $7.25 billion to settle decade-old claims regarding its weedkiller Roundup [2].
Stock Performance defies Analyst Caution
While facing these legal headwinds, Johnson & Johnson’s stock performance has shown remarkable resilience, trading significantly above the consensus expectations of Wall Street analysts [1]. As of the market close on February 27, 2026, shares of JNJ were priced at $248.81 [1]. This valuation stands in contrast to the average twelve-month price target of $232.70 set by 27 analysts, representing a divergence of 16.11 per share above the average forecast [1]. Consequently, the current price implies a forecasted downside of approximately 6.48% if the stock were to regress to the mean analyst target [1]. Despite the pricing disparity, the overall sentiment remains positive; the stock holds a “Moderate Buy” consensus rating, with 17 analysts issuing buy ratings, 9 holding, and 1 assigning a strong buy rating over the last year [1].